HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AB&B BIO-TECH-B

38.600

-7.400-16.09%

Volume:1.09M

Turnover:43.71M

Market Cap:15.17B

PE:-47.19

High:47.060

Open:46.980

Low:37.700

Close:46.000

52wk High:73.000

52wk Low:33.000

Shares:393.00M

HK Float Shares:296.36M

Volume Ratio:0.44

T/O Rate:0.37%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.818

ROE:--

ROA:--

PB:395.94

PE(LYR):-47.19

PS:41.16

Loading ...

Overview Company News Filings

Ab&B Bio-Tech Strikes Overseas Vaccine Deal With Walvax Hong Kong; Shares Fall 13%

MT Newswires Live

AB&B BIO-TECH-B Enters Strategic Pact with Hong Kong Watson for Overseas Market Expansion of Subunit Flu Vaccine

AB&B Bio-Tech-B (02627.HK) Signs Strategic Cooperation Agreement with Walvax Hong Kong to Globalise Trivalent Influenza Vaccine

Bulletin Express

AB&B BIO-TECH-B (02627) Enters Strategic Pact with Hong Kong Watson for Overseas Expansion of Subunit Flu Vaccine

AB&B Bio-Tech signs strategic cooperation agreement with Walvax Hong Kong for overseas flu vaccine expansion

Ab&B Bio Tech - Enters Strategic Cooperation Agreement With Walvax Hong Kong Ltd

THOMSON REUTERS

Ab&B Bio Tech Co Ltd Js - Core Product for Expansion Is Trivalent Subunit Influenza Vaccine Huierkangxin 3

THOMSON REUTERS

AB&B BIO-TECH-B Surges Over 7% in Late Trading on Inclusion in Stock Connect and FDA Clearance for Monkeypox Vaccine

AB&B BIO-TECH-B (02627) Activates Second Growth Engine with Impending Commercial Scale-Up and Pipeline Milestones

AB&B BIO-TECH-B (02627) Gains FDA IND Approval for mRNA Mpox Vaccine

Bulletin Express

AB&B BIO-TECH-B's mRNA Monkeypox Vaccine Receives FDA Clearance for Clinical Trials

U.S. FDA Approves IND for AB&B Bio-Tech mRNA Mpox Vaccine Candidate

Ab&B Bio Tech Co Ltd Js - Ind Approval by U.S. FDA for Mrna Mpox Vaccine

THOMSON REUTERS

Ab&B Bio-Tech (02627) Reports Monthly Return for February 2026

Bulletin Express

Innovative Differentiation and Positive Earnings Forecast Set Stage for Davis Double at AB&B BIO-TECH-B (02627)

Ab&B Bio-Tech (2627) Reports Significant Revenue Growth and Reduced Net Loss for FY2025

Bulletin Express

AB&B BIO-TECH-B (02627) Forecasts Annual Revenue of Approximately 4.46 to 4.93 Billion Yuan, Up 71.8% to 89.9% Year-on-Year

Ab&B Bio Tech Co Ltd Js - Expected to Record Revenue in Range of Around RMB446 Mln to RMB493 Mln for FY2025

THOMSON REUTERS

AB&B Bio-Tech forecasts FY2025 net loss narrows to RMB157 million–RMB197 million

Hong Kong Stocks Inch Up in Shortened Trading Session Ahead of Lunar New Year Break; Samsonite Gains on U.S. Listing Plan

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02627/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02627","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","market":"HK","secType":"STK","nameCN":"AB&B BIO-TECH-B","latestPrice":38.6,"timestamp":1773734894005,"preClose":46,"halted":0,"volume":1092944,"delay":0,"changeRate":-0.16086956521739126,"floatShares":296361845,"shares":393000000,"eps":-0.8180503473947354,"marketStatus":"Not Yet Opened","change":-7.4,"latestTime":"03-17 16:08:14","open":46.98,"high":47.06,"low":37.7,"amount":43706147,"amplitude":0.203478,"askPrice":38.68,"askSize":800,"bidPrice":38.6,"bidSize":2800,"shortable":3,"etf":0,"ttmEps":-0.7114421622638256,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1773797400000},"marketStatusCode":0,"adr":0,"listingDate":1754841600000,"exchange":"SEHK","adjPreClose":46,"openAndCloseTimeList":[[1773711000000,1773720000000],[1773723600000,1773734400000]],"volumeRatio":0.4364216478784109,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02627\",,,,,undefined,":{"symbol":"02627","floatShares":296361845,"roa":"--","roe":"--","lyrEps":-0.81805,"volumeRatio":0.4364216478784109,"shares":393000000,"dividePrice":0,"high":47.06,"amplitude":0.203478,"preClose":46,"low":37.7,"week52Low":33,"pbRate":"395.94","psRate":"41.16","week52High":73,"institutionHeld":0,"latestPrice":38.6,"committee":0.555556,"eps":-0.8180503473947354,"divideRate":0,"volume":1092944,"delay":0,"ttmEps":-0.7114421622638256,"open":46.98,"prevYearClose":40.24,"prevWeekClose":57.3,"prevMonthClose":54.1,"prevQuarterClose":40.24,"fiveDayClose":60,"twentyDayClose":51.3,"sixtyDayClose":40.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02627\",params:#limit:5,,,undefined,":[{"date":"2025-08-28","symbol":"02627","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756344600000,"name":null,"time":"","dateTimestamp":1756310400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02627\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02627\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02627\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02627","date":"2026-03-16","current":-54.251573,"percent":0.428571,"low":-109.844469,"twenty":-78.795285,"median":-66.921393,"eighty":-64.230596,"high":-18.07815,"avg":-70.405616,"sd":9.721152,"marketCap":18098359600},"quantilePoints":[{"date":"2025-08-08","current":-18.07815,"twenty":-18.07815,"median":-18.07815,"eighty":-18.07815,"marketCap":5586884920},{"date":"2025-08-15","current":-60.155426,"twenty":-60.155426,"median":-56.438909,"eighty":-42.414982,"marketCap":18562621868},{"date":"2025-08-22","current":-65.870069,"twenty":-65.897052,"median":-63.746879,"eighty":-55.654938,"marketCap":20262293900},{"date":"2025-08-29","current":-64.920623,"twenty":-66.830053,"median":-65.395346,"eighty":-57.22288,"marketCap":20065572600},{"date":"2025-09-05","current":-62.716917,"twenty":-66.416243,"median":-63.912829,"eighty":-60.155426,"marketCap":19365244772},{"date":"2025-09-12","current":-62.655098,"twenty":-66.251138,"median":-63.08644,"eighty":-59.27469,"marketCap":19380982476},{"date":"2025-09-19","current":-81.048551,"twenty":-68.315951,"median":-63.912829,"eighty":-59.882299,"marketCap":19888523430},{"date":"2025-09-26","current":-77.095946,"twenty":-77.153546,"median":-65.395346,"eighty":-60.155426,"marketCap":18869507096},{"date":"2025-10-03","current":-76.784092,"twenty":-77.86406,"median":-66.074095,"eighty":-61.128611,"marketCap":18838031688},{"date":"2025-10-10","current":-75.450727,"twenty":-78.338288,"median":-66.623148,"eighty":-61.710077,"marketCap":18483933348},{"date":"2025-10-17","current":-70.044793,"twenty":-77.841467,"median":-68.315951,"eighty":-62.332762,"marketCap":17146228508},{"date":"2025-10-24","current":-70.694139,"twenty":-77.356453,"median":-69.86748,"eighty":-62.632094,"marketCap":17311474400},{"date":"2025-10-31","current":-64.652972,"twenty":-77.130506,"median":-68.586563,"eighty":-62.679826,"marketCap":15855736780},{"date":"2025-11-07","current":-65.014442,"twenty":-77.0495,"median":-67.012733,"eighty":-63.012535,"marketCap":15934425300},{"date":"2025-11-14","current":-69.152784,"twenty":-76.901535,"median":-66.692171,"eighty":-63.572329,"marketCap":16996720320},{"date":"2025-11-21","current":-64.47659,"twenty":-76.671062,"median":-66.251138,"eighty":-63.813259,"marketCap":15839999076},{"date":"2025-11-28","current":-66.221916,"twenty":-76.081201,"median":-65.883561,"eighty":-63.948664,"marketCap":16327867900},{"date":"2025-12-05","current":-64.387851,"twenty":-75.140133,"median":-65.711289,"eighty":-64.052768,"marketCap":15902949892},{"date":"2025-12-12","current":-65.09579,"twenty":-74.230454,"median":-65.51992,"eighty":-64.060512,"marketCap":16107540044},{"date":"2025-12-19","current":-64.75238,"twenty":-73.314016,"median":-65.09579,"eighty":-64.128623,"marketCap":16060326932},{"date":"2025-12-24","current":-63.88714,"twenty":-72.937878,"median":-65.019631,"eighty":-64.128296,"marketCap":15895081040},{"date":"2026-01-02","current":-63.38466,"twenty":-72.68164,"median":-64.955716,"eighty":-63.907691,"marketCap":15832130224},{"date":"2026-01-09","current":-64.42138,"twenty":-72.421694,"median":-64.920623,"eighty":-63.984499,"marketCap":16131146600},{"date":"2026-01-16","current":-79.012958,"twenty":-72.68164,"median":-65.002626,"eighty":-63.984499,"marketCap":19849179170},{"date":"2026-01-23","current":-80.264585,"twenty":-74.684429,"median":-65.09579,"eighty":-64.012742,"marketCap":20144261120},{"date":"2026-01-30","current":-75.685884,"twenty":-76.499114,"median":-65.441715,"eighty":-64.034272,"marketCap":19081966100},{"date":"2026-02-06","current":-72.661412,"twenty":-75.84841,"median":-65.678772,"eighty":-64.110439,"marketCap":18365900568},{"date":"2026-02-13","current":-79.706332,"twenty":-76.558032,"median":-65.817553,"eighty":-64.12895,"marketCap":20262293900},{"date":"2026-02-20","current":-82.611175,"twenty":-76.790716,"median":-65.857422,"eighty":-64.132361,"marketCap":20970490580},{"date":"2026-02-27","current":-82.941496,"twenty":-77.55936,"median":-66.221916,"eighty":-64.146544,"marketCap":21285244660},{"date":"2026-03-06","current":-81.374491,"twenty":-78.249638,"median":-66.33369,"eighty":-64.163416,"marketCap":20714752890},{"date":"2026-03-13","current":-88.155391,"twenty":-78.824484,"median":-66.830053,"eighty":-64.221195,"marketCap":22544260980},{"date":"2026-03-16","current":-71.018309,"twenty":-78.795285,"median":-66.921393,"eighty":-64.230596,"marketCap":18098359600}],"updateTime":1773787233921},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02627\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619438766","title":"Ab&B Bio-Tech Strikes Overseas Vaccine Deal With Walvax Hong Kong; Shares Fall 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619438766","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619438766?lang=en_us&edition=fundamental","pubTime":"2026-03-16 11:10","pubTimestamp":1773630634,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech  said it has entered into a cooperation agreement with Walvax Hong Kong to expand overseas markets for its subunit influenza vaccine, according to a March 13 Hong Kong bourse filing.Shares of the biotech firm were down more than 13% in Monday morning trade.The companies will cooperate on overseas registration, sales, and commercialization of the group's products, with the trivalent subunit influenza vaccine Huierkangxin 3 as the core product for international expansion.The partnership will leverage Walvax Hong Kong's overseas market resources and distribution networks to accelerate expansion into Southeast Asia, Latin America, the Middle East, and other Southern Hemisphere markets.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1177465844","title":"AB&B BIO-TECH-B Enters Strategic Pact with Hong Kong Watson for Overseas Market Expansion of Subunit Flu Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1177465844","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177465844?lang=en_us&edition=fundamental","pubTime":"2026-03-15 16:00","pubTimestamp":1773561654,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that the company has entered into a strategic cooperation agreement with Watson Biotech (Hong Kong) Limited concerning the overseas market expansion of a subunit...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1129349142","title":"AB&B Bio-Tech-B (02627.HK) Signs Strategic Cooperation Agreement with Walvax Hong Kong to Globalise Trivalent Influenza Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1129349142","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129349142?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:03","pubTimestamp":1773396227,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech CO., LTD. JS (AB&B Bio-Tech-B, 02627.HK) has entered into a strategic cooperation agreement with Walvax Hong Kong Limited, a wholly-owned subsidiary of Shenzhen-listed Walvax...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"1175657066","title":"AB&B BIO-TECH-B (02627) Enters Strategic Pact with Hong Kong Watson for Overseas Expansion of Subunit Flu Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1175657066","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175657066?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:54","pubTimestamp":1773395664,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that the company has entered into a strategic cooperation agreement with Watson Biotech (Hong Kong) Limited concerning the overseas market expansion of a subunit...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2619198027","title":"AB&B Bio-Tech signs strategic cooperation agreement with Walvax Hong Kong for overseas flu vaccine expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198027","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619198027?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:46","pubTimestamp":1773395172,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech entered a strategic cooperation agreement with Walvax Hong Kong to support overseas market registration and commercialization of AB&B Bio-Tech’s products. The collaboration focuses on AB&B Bio-Tech’s trivalent subunit influenza vaccine Huierkangxin 3, which was approved for marketing in January 2026. The agreement targets expansion into markets including Southeast Asia, Latin America, and the Middle East. Walvax Hong Kong is a wholly owned subsidiary of Walvax Biotech.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 13, 2026, and is solely res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL1LWc5K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","300142","BK0070","BK0239","BK1161","BK0077","02627"],"gpt_icon":0},{"id":"2619198062","title":"Ab&B Bio Tech - Enters Strategic Cooperation Agreement With Walvax Hong Kong Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198062","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619198062?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:45","pubTimestamp":1773395159,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN40022P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2619198025","title":"Ab&B Bio Tech Co Ltd Js - Core Product for Expansion Is Trivalent Subunit Influenza Vaccine Huierkangxin 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619198025?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:45","pubTimestamp":1773395159,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN40022P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02627","BK1161"],"gpt_icon":0},{"id":"1146910619","title":"AB&B BIO-TECH-B Surges Over 7% in Late Trading on Inclusion in Stock Connect and FDA Clearance for Monkeypox Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1146910619","media":"Stock News","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146910619?lang=en_us&edition=fundamental","pubTime":"2026-03-09 15:25","pubTimestamp":1773041110,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) saw its shares rise more than 7% during the late trading session. At the time of writing, the stock was up 7.31%, trading at HK$56.5, with a turnover of HK$87.528 million. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","159646","BK4585","VXUS","02627","BK1161"],"gpt_icon":0},{"id":"1102287845","title":"AB&B BIO-TECH-B (02627) Activates Second Growth Engine with Impending Commercial Scale-Up and Pipeline Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=1102287845","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102287845?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:44","pubTimestamp":1772617474,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) has recently announced two significant positive developments, drawing market attention. On one hand, the company's self-developed trivalent influenza virus subunit vaccine,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1125468083","title":"AB&B BIO-TECH-B (02627) Gains FDA IND Approval for mRNA Mpox Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1125468083","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125468083?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:04","pubTimestamp":1772615047,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co., Ltd. JS (AB&B Bio-Tech-B (02627)) announced that the U.S. Food and Drug Administration approved the Investigational New Drug application for its self-developed mRNA mpox vaccine...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"1198328209","title":"AB&B BIO-TECH-B's mRNA Monkeypox Vaccine Receives FDA Clearance for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1198328209","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198328209?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:40","pubTimestamp":1772613621,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that in the United States, the Food and Drug Administration (FDA) has permitted the Investigational New Drug (IND) application for the group's self-developed mRNA...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627","159646","BK1161"],"gpt_icon":0},{"id":"2616958093","title":"U.S. FDA Approves IND for AB&B Bio-Tech mRNA Mpox Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2616958093","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616958093?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:33","pubTimestamp":1772613191,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co. Ltd. JS said the U.S. Food and Drug Administration has approved its Investigational New Drug application for a self-developed mRNA mpox vaccine candidate, allowing the program to proceed to clinical development in the United States. The company stated this is China’s first and the world’s third mRNA mpox vaccine candidate to receive FDA IND approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDLb8tw1c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2616607580","title":"Ab&B Bio Tech Co Ltd Js - Ind Approval by U.S. FDA for Mrna Mpox Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2616607580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616607580?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:32","pubTimestamp":1772613179,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS0V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1124130150","title":"Ab&B Bio-Tech (02627) Reports Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1124130150","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124130150?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:42","pubTimestamp":1772444545,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS (stock code: 02627) released the monthly return on movements in securities for the period ended 28 February 2026. The total authorized share capital stood at 393.44 million...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"1173944245","title":"Innovative Differentiation and Positive Earnings Forecast Set Stage for Davis Double at AB&B BIO-TECH-B (02627)","url":"https://stock-news.laohu8.com/highlight/detail?id=1173944245","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173944245?lang=en_us&edition=fundamental","pubTime":"2026-02-26 17:14","pubTimestamp":1772097260,"startTime":"0","endTime":"0","summary":"Following the announcement on January 30th of this year regarding the successful market approval of the nation's first and only trivalent influenza virus subunit vaccine for the entire population,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"gpt_icon":0},{"id":"1198738554","title":"Ab&B Bio-Tech (2627) Reports Significant Revenue Growth and Reduced Net Loss for FY2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1198738554","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198738554?lang=en_us&edition=fundamental","pubTime":"2026-02-26 17:02","pubTimestamp":1772096535,"startTime":"0","endTime":"0","summary":"Ab&B Bio-Tech CO., LTD. JS (Stock Code: 2627) has issued a profit alert indicating an expected revenue of 446.00 million to 493.00 million renminbi for the year ended December 31, 2025, reflecting a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02627"],"gpt_icon":0},{"id":"1198817376","title":"AB&B BIO-TECH-B (02627) Forecasts Annual Revenue of Approximately 4.46 to 4.93 Billion Yuan, Up 71.8% to 89.9% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1198817376","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198817376?lang=en_us&edition=fundamental","pubTime":"2026-02-26 16:54","pubTimestamp":1772096078,"startTime":"0","endTime":"0","summary":"AB&B BIO-TECH-B (02627) announced that the group anticipates reporting revenue of approximately RMB 4.46 billion to RMB 4.93 billion for the 2025 fiscal year. This represents an increase of about...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2614101321","title":"Ab&B Bio Tech Co Ltd Js - Expected to Record Revenue in Range of Around RMB446 Mln to RMB493 Mln for FY2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2614101321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614101321?lang=en_us&edition=fundamental","pubTime":"2026-02-26 16:44","pubTimestamp":1772095461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZL2B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02627","BK1161"],"gpt_icon":0},{"id":"2614132430","title":"AB&B Bio-Tech forecasts FY2025 net loss narrows to RMB157 million–RMB197 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614132430","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614132430?lang=en_us&edition=fundamental","pubTime":"2026-02-26 16:44","pubTimestamp":1772095451,"startTime":"0","endTime":"0","summary":"AB&B Bio-Tech Co. Ltd. JS expects FY2025 revenue of about RMB446 million to RMB493 million, up 71.8% to 89.9% from RMB259.6 million in FY2024. It also forecasts a FY2025 net loss of about RMB157 million to RMB197 million, narrowing 23.9% to 39.3% from a RMB258.7 million loss a year earlier.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDLb4GnWb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02627"],"gpt_icon":0},{"id":"2611103539","title":"Hong Kong Stocks Inch Up in Shortened Trading Session Ahead of Lunar New Year Break; Samsonite Gains on U.S. Listing Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2611103539","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611103539?lang=en_us&edition=fundamental","pubTime":"2026-02-16 12:41","pubTimestamp":1771216869,"startTime":"0","endTime":"0","summary":"Hong Kong equities finished slightly higher on Monday in a shortened trading session ahead of the Lunar New Year holidays.The Hang Seng Index rose 138.82 points, or 0.5%, to finish at 26,705.94, while the Hang Seng China Enterprises Index added 37.61 points, or 0.4%, to close at 9,070.32.Trading volumes were light as investors locked in profits and reduced exposure ahead of the holiday period.Markets are also looking ahead to key data later in the week, including global manufacturing surveys and U.S. fourth-quarter gross domestic product figures due on Friday.Median forecasts point to annualized U.S. growth of 3%, easing from 4.4% in the previous quarter, according to a Reuters report.Hong Kong's financial markets will be closed for the Lunar New Year holidays and reopen on Friday, Feb. 20.In corporate news, AB&B Bio-Tech  closed over 10% higher after saying it will be added to the Hang Seng Composite Index from March 9.Samsonite International  also gained more than 2% after saying it ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0149534421.HKD","LU2065170008.USD","LU0572940350.SGD","LU0264606111.USD","LU2065169927.USD","LU0251143458.SGD","LU0607220059.USD","HHImain","BK1602","SMSEY","MHImain","LU1166156734.SGD","BK1161","LU0572939691.SGD","LU0702159699.USD","LU2065171311.SGD","01910","SG9999004303.SGD","BK1577","SG9999004311.SGD","02627","SG9999011746.SGD","BK1500","LU0702159343.USD","513600","BK1227","SGXZ23171101.USD","LU1880383366.USD","LU2065171402.SGD","02833","MCHmain","LU0823040885.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":55,"code":"91000000","status":"200"}]}}